Treatment of patients with chronic hepatitis C and cirrhosis

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 197-200

  Bonino, F ^a,b   Oliveri, F ^a,b   Colombatto, P ^a,b   Coco, B ^a,b   Mura, D ^a,b   Realdi, G ^a,b   Brunetto, M R ^a,b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Antiviral therapy; Chronic hepatitis C; Cirrhosis; HCV; Hepatocellular carcinoma; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECHOGRAPHY; HEPATITIS C; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; PORTAL HYPERTENSION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033432819     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80401-2     Document Type: Conference Paper

References (18)

1. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F et al. Prevalence, risk factors and genotype distribution of hepatitis C virus infection in the general population. A community-based survey in Southern Italy. Hepatology 1997: 26: 1006-1011.
2. Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997: 26: 155-205.
3. Alter MJ. The epidemiology of hepatitis C in the west. Semin Liver Dis 1995: 15: 5-14.
4. Alberti A. Viral hepatitis. Ballière's Clin Gastroenterol 1996: 2nd vol. 10.
5. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL et al. Long term mortality after transfusion-associated nonA, non-B hepatitis. N EngI J Med 1992: 327: 1906-1911.
6. Poynard T, Bedossa P, Opolon P and OBSVIRC, METAVIR and DOSVIRC groups Lancet 1997: 349: 825-832.
7. Nishigushi-S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995: 346: 1051-1055.
8. Mazzella G, Accogli E, Sottili S, Festi G, Orsini M, Salzetta A et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996: 24: HI147.
9. Koretz RL. Interferon and hepatocellular carcinoma. Lancet 1996: 347: 194.
10. Andreone P, Cursaro C, Gramenzi A et al. Interferon and hepatocellular carcinoma. Lancet 1996: 347: 195.
11. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997: 112:463-472.
12. Brunetto MR, Oliveri F, Koehler M, Zahm F, Bonino F and International Interferon-ot Hepatocellular Carcinoma Study Group. Effect of interferon-a on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998: 351: 1535-1539.
13. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998: 27: 1435-1440.
14. Sofia S, Casali A, Buscarini E, Castagneti E, Rapaccini GL, Levantes! F et al. Effect of lymphoblastoid IFN in the treatment of liver cirrhosis and prevention of HCC. Ital J Gastroenterol Hepatol 1998: 30: SI, abs. 11 (A31).
15. Mura D, Deliperi R, Fastame L, Carlini A, Cossu PA, Pisanu G et al. Five years follow-up after interferon therapy in HCV-positive compensated cirrhosis. Ital J Gastroenterol Hepatol 1998: 30: S2, abs. 93 (A 114).
16. Fattovich G, Giustina G, Favarato S, Ruol A and Investigators of the Italian Association for the Study of the Liver (A1SF) A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996: 24: 3847.
17. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998: 27: 1394-1402.
18. AISF Committee for Antiviral Therapy: guidelines for the treatment of chronic viral hepatitis. Ital J Gastroenterol Hepatol 1997: 29: 583-596.